<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39333909</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants.</ArticleTitle><Pagination><StartPage>1049</StartPage><MedlinePgn>1049</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1049</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09861-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We assessed the prognostic value of serological humoral markers measured one month after the last dose of the primary COVID-19 vaccine course for predicting the risk of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection over the following six months in specific populations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">ANRS0001SCOV-POPART is a French nationwide multicenter prospective observational cohort study assessing the immune response to Covid-19 vaccines routinely administered to 11 subgroups of patients with chronic disease and a control group. Participants from the ANRS0001S COV-POPART were included if they received at least two doses of Covid-19 vaccine for the primary vaccine course, had measurements of anti-Spike, anti-receptor binding domain (RBD) IgG-specific or neutralizing antibodies one month after the end of the primary vaccine course, without being infected by SARS-CoV-2 before the measurement. SARS-CoV-2 infections defined by a positive PCR/antigenic test or seroconversion to detectable anti nucleocapsid antibodies were evaluated until the first COVID-19 booster injection. Cox proportional hazards models taking into account interval-censored data were implemented to estimate the association between each antibody level and the risk of SARS-CoV-2 infection. Predictive performances were evaluated by the area under the receiving operating characteristic curve (AUROC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two thousand five hundred seventy adults from a specific population and 1,123 from the control group were included. The cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement were 6.0% 95% confidence interval: [5.0; 7.9] and 10.1% 95% confidence interval: [8.3; 11.9], respectively. Higher levels of anti-Spike IgG antibody were associated with a lower risk of SARS-CoV-2 infections in the control group, but not in the specific populations. Among the specific populations, AUROC were 74.5%, 74.9%, and 72.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively. AUROC were superior in the specific populations, 82.0%, 81.2%, and 81.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Vaccine-induced antibody response after the primary course of Covid-19 infection only moderately discriminated between participants developing a SARS-CoV-2 infection during the Omicron wave.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT04824651 (first posted: 2021-04-01).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chalouni</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, U1219, Bordeaux, F-33000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loubet</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Service des Maladies infectieuses et Tropicales, CHU de Nîmes, Nîmes, France; INSERM U1047 - Université de Montpellier, Nîmes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lhomme</LastName><ForeName>Edouard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, U1219, Bordeaux, F-33000, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INRIA SISTM team, Talence, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service d'Information médicale, CHU de Bordeaux, Bordeaux, F-33000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ninove</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unite des Virus Emergents, Aix-Marseille Université, Institut de Recherche pour le Développement 190, Inserm 1207, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrou</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de Transplantation Rénale, Pitié Salpêtrière, APHP, Sorbonne Université, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blay</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Centre Léon-Bérard, Département de cancérologie médicale, Lyon, France; Université Claude Bernard Lyon, Unicancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hourmant</LastName><ForeName>Maryvonne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de Néphrologie-Immunologie clinique, CHU Nantes, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Seze</LastName><ForeName>Jérome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CIC INSERM 1434, Strasbourg university hospital, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laville</LastName><ForeName>Martine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM U1191/UMR 5203, Université de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Lyon, Université de Lyon, Association Française d'Etudes et de Recherche de l'Obésité, INSERM, F-CRIN -French Obesity Research Centre of Excellence (FORCE) Network, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laviolle</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Université de Rennes, CHU Rennes, INSERM, CIC 1414, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lelièvre</LastName><ForeName>Jean-Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Vaccine Research Institute, INSERM et APHP, Hôpital H. Mondor, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morel</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Département de Rhumatologie, CHU et Université de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quoc</LastName><ForeName>Stéphanie Nguyen</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Centre d'Immunologie et des Maladies Infectieuses-Paris, APHP-Sorbonne Université, INSERM U1135, CNRS ERL 8255, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spano</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>INSERM, institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), équipe TheraVir, AP-HP, Sorbonne université, hôpital universitaire Pitié-Salpêtrière, Oncologie médicale, CLIP2 Galilée, Sorbonne université, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terrier</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Cochin, APHP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiebaut</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Département d'Hématologie, CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viallard</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Hôpital Haut-Lévêque, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrtovsnik</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département Hospitalo-Universitaire Fire, Service de Néphrologie, Hôpital Bichat-Claude Bernard, APHP, Université de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Circosta</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>INSERM, SC10-US019 Essais thérapeutiques et Maladies Infectieuses, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barquin</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, U1219, Bordeaux, F-33000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gharib</LastName><ForeName>Mariam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ANRS Maladies infectieuses émergentes (ANRS MIE), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartour</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service d'Immunologie biologique, Hôpital européen Georges Pompidou/APHP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parfait</LastName><ForeName>Béatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre de ressources Biologiques, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiébaut</LastName><ForeName>Rodolphe</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, U1219, Bordeaux, F-33000, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INRIA SISTM team, Talence, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service d'Information médicale, CHU de Bordeaux, Bordeaux, F-33000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Université Paris Saclay, CESP Inserm U1018, APHP Service de Santé Publique, le Kremlin- Bicêtre, 94276, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lamballerie</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unite des Virus Emergents, Aix-Marseille Université, Institut de Recherche pour le Développement 190, Inserm 1207, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launay</LastName><ForeName>Odile</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Service des Maladies infectieuses et Tropicales, CHU de Nîmes, Nîmes, France; INSERM U1047 - Université de Montpellier, Nîmes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Centre d'Investigation Clinique Cochin Pasteur, Hôpital Cochin/APHP, INSERM CIC 1417, Paris, France; Université de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wittkop</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, U1219, Bordeaux, F-33000, France. linda.wittkop@u-bordeaux.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INRIA SISTM team, Talence, France. linda.wittkop@u-bordeaux.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service d'Information médicale, CHU de Bordeaux, Bordeaux, F-33000, France. linda.wittkop@u-bordeaux.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ANRS0001S COV-POPART study group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04824651</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Prediction</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Specific populations</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>PL has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astrazeneca, GlaxoSmithKline, Janssen, Merck Sharp &amp; Dohme, Pfizer, Sanofi Pasteur and Support for attending meetings and/or travel from Pfizer, Sanofi Pasteur. JM has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Biogen, BMS, Boerhinger Ingelheim, Galapagos, GSK, Fresenius Kabi, Lilly, Mylan, Novartis, Pfizer, Sanofi and grants outside the submitted work from Lilly, Novartis. JPS has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer and Astrazeneca. OL has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi Pasteur; Pfizer, Janssen and, non-financial support from Sanofi Pasteur; Pfizer, Janssen, GlaxoSmithKline and grant from GlaxoSmithKline. The other authors declare having no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333909</ArticleId><ArticleId IdType="pmc">PMC11429529</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09861-5</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09861-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond Engl. 2021;397(10269):99–111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Haute Autorité de Santé. Avis n° 2022.0004/AC/SESPEV du 13 janvier 2022 du collège de la Haute Autorité de santé relatif à la place du vaccin Janssen en seconde dose et en dose de rappel dans la stratégie de vaccination contre la Covid-19. Available from: https://www.has-sante.fr/jcms/p_3309607/fr/avis-n-2022-0004/ac/sespev-du-13-janvier-2022-du-college-de-la-haute-autorite-de-sante-relatif-a-la-place-du-vaccin-janssen-en-seconde-dose-et-en-dose-de-rappel-dans-la-strategie-de-vaccination-contre-la-covid-19. Cited 2023 Jan 17.</Citation></Reference><Reference><Citation>Loubet P, Wittkop L, Tartour E, Parfait B, Barrou B, Blay JY, et al. A French cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med. 2021;27(8):1319–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">34253930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al. BNT162b2 mRNA Covid-19 vaccine in a Nationwide Mass Vaccination setting. N Engl J Med. 2021;384(15):1412–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet Lond Engl. 2021;397(10287):1819–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142841</ArticleId><ArticleId IdType="pubmed">34210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021;373(6561):1372–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691522</ArticleId><ArticleId IdType="pubmed">34385356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet Lond Engl. 2022;399(10323):437–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769664</ArticleId><ArticleId IdType="pubmed">35065011</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron Wave compared with previous waves. JAMA. 2022;327(6):583–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719272</ArticleId><ArticleId IdType="pubmed">34967859</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-hodgkin lymphoma. Blood Adv. 2021;5(16):3053–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362658</ArticleId><ArticleId IdType="pubmed">34387648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385563</ArticleId><ArticleId IdType="pubmed">34379917</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev. 2022;310(1):6–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348242</ArticleId><ArticleId IdType="pubmed">35661178</ArticleId></ArticleIdList></Reference><Reference><Citation>Loubet P, Wittkop L, Ninove L, Chalouni M, Barrou B, Blay JY, et al. One-month humoral response following two or three doses of mRNA Covid-19 vaccines as primary vaccination in specific populations in France: first results from the ANRS0001S COV-POPART cohort. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;S1198-743X(22):00522–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9562615</ArticleId><ArticleId IdType="pubmed">36252789</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–97.</Citation><ArticleIdList><ArticleId IdType="pubmed">24027076</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">25560730</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Lee J, Ta C, Soroush A, Rogers JR, Kim JH, et al. Risk factors associated with SARS-CoV-2 breakthrough infections in fully mRNA-Vaccinated individuals: retrospective analysis. JMIR Public Health Surveill. 2022;8(5):e35311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132195</ArticleId><ArticleId IdType="pubmed">35486806</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamal JM, Appana S, Wang M, Leon-Novelo L, Bakota E, Ye Y, et al. Trends and correlates of breakthrough infections with SARS-CoV-2. Front Public Health. 2022;10:856532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127615</ArticleId><ArticleId IdType="pubmed">35619825</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat Rev Endocrinol. 2022;18(2):75–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8647056</ArticleId><ArticleId IdType="pubmed">34873287</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldridge RW, Yavlinsky A, Nguyen V, Eyre MT, Shrotri M, Navaratnam AMD, et al. SARS-CoV-2 antibodies and breakthrough infections in the virus watch cohort. Nat Commun. 2022;13(1):4869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9387883</ArticleId><ArticleId IdType="pubmed">35982056</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52-61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592563</ArticleId><ArticleId IdType="pubmed">34806056</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y, McDermott AB, Benkeser D, Roels S, Stieh DJ, Vandebosch A, et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat Microbiol. 2022;7(12):1996–2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10166187</ArticleId><ArticleId IdType="pubmed">36357712</ArticleId></ArticleIdList></Reference><Reference><Citation>Baerends EAM, Hvidt AK, Reekie J, Søgaard OS, Stærke NB, Raben D, et al. SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection. iScience. 2023;26(9):107621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10481355</ArticleId><ArticleId IdType="pubmed">37682631</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín Pérez C, Aguilar R, Jiménez A, Salmerón G, Canyelles M, Rubio R, et al. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination. BMC Med. 2024;22(1):103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10921636</ArticleId><ArticleId IdType="pubmed">38454385</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking U, Havervall S, Norin NG, Bladh O, Christ W, Gordon M, et al. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. Nat Commun. 2023;14(1):1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10031702</ArticleId><ArticleId IdType="pubmed">36949041</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. 2022;28(5):1042–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9117133</ArticleId><ArticleId IdType="pubmed">35241844</ArticleId></ArticleIdList></Reference><Reference><Citation>Atti A, Insalata F, Carr EJ, Otter AD, Castillo-Olivares J, Wu M, et al. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study. J Infect. 2022;85(5):545–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9458758</ArticleId><ArticleId IdType="pubmed">36089104</ArticleId></ArticleIdList></Reference><Reference><Citation>Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 Vaccine efficacy clinical trial. Ann Intern Med. 2022;175:1258–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258784</ArticleId><ArticleId IdType="pubmed">35785530</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res. 2020;181:104880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362788</ArticleId><ArticleId IdType="pubmed">32679056</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>